Kaufempfehlung Neuralstem Inc - 500 Beiträge pro Seite

[kfz]

DGAP-News: Bulle & Bär Ltd. (deutsch)
Bulle & Bär Research: Kaufempfehlung zu Neuralstem Inc.

EquityStory AG-News: Bulle & Bär Ltd. / Schlagwort(e): Prognose/Studie Bulle & Bär Research: Kaufempfehlung zu Neuralstem Inc.

24.01.2011 / 09:20

Anzeigen von Google Gratis Dax Ausblick 2011
Sofort Gratis Download: Trends zuverlässig prognostizieren
Chartanalyse-Trends.de
..---------------------------------------------------------------------

Die Experten von Bulle & Bär Research sehen in der Kurskonsolidierung des Amex gelisteten Biotherapieunternehmens Neuralstem Inc. ( ISIN: US64127R3021 NEURALSTEM INC. DL-,01 , WKN: A0MNDN, Symbol: CUR) derzeit eine interessante Einstiegsmöglichkeit mit einem mittelfristigen Kursziel von 5 USD.

Neuralstems Stammzellentherapiesystem ermöglicht es erstmalig neuronale Stammzellen des menschlichen Gehirns und der Wirbelsäule in kommerziellen Mengen zu produzieren. Unter großem Medieninteresse hat kürzlich die erste Studie zur Anwendung dieser Technologie bei ALS begonnen.

Anzeigen von Google Aktien mit Superkraft
Diese Aktie muss unbedingt 400% hoch. Gratis Tipp!
www.topaktienreport.de
..Neuartiges Antidepressivum als Umsatzschlager?

Des weiteren hat Neuralstem ein neuartiges Antidepressivum namens NSI-189 entwickelt, welches die Behandlung von Depressionen und anderen Krankheiten mit Gedächtnisschwund schlagartig revolutionieren könnte. NSI-189 stimuliert das Wachstum neuer Zellen im Hippocampus - der zentralen Schnittstelle für Gedächtnisleistungen aller Art. Grundlage der Studie ist eine neue Theorie der Depression, wonach chronischer Stress über Hormone zu Zellverlust im Hippocampus führt, durch dessen Beeinträchtigung letztlich auch depressive Zustände entstehen können.

Patente mit Anwendungspotential bei über 40 Millionen Patienten

Ingesamt verfügt Neuralstem über diverse Patente in der Stammzellentherapie des zentralen wie peripheren Nervensystems sowie beim Wirkstofftransport. Mit zunehmenden Fortschritten in der Stammzellentherapie insgesamt kann mit einer zunehmenden Kommerzialisierung dieser Patente gerechnet werden.

Kapitalerhöhungen erzeugen großes Vertrauen in zukünftige Produktentwicklung

Die letzte Finanzierungsgrunde über 10 Millionen USD zu 2.80 USD mit Optionen zu 3.25 USD / Aktie brachte den Einstieg zahlreicher institutioneller Investoren mit sich und beflügelte den Kurs auf bis zu 3.50 USD. Der hohe Ausgabepreis - wie bei der Finanzierungsgrunde zuvor mit einem Premium auf den Börsenkurs - unterstrich die Zuversicht institutioneller Investoren bezüglich einer erfolgreichen Produktentwicklung.

Kurskonsolidierung als Einstiegschance

Vom Niveau bei 3.50 USD ist der Kurs derzeit bis nahe an das 52-Wochen Tief bei 1.71 USD zurückgekommen. Dies bietet spekulativen Anlegern eine interessante Einstiegsmöglichkeit, da auf diesem Kursniveau die Chancen gegenüber den Risiken wieder die Oberhand gewinnen sollten.

Aufgrund der guten Aufstellung im Zukunftsmarkt Stammzellentherapie, der Chance auf ein Blockbuster Medikament und der vielfältigen zukünftigen Entwicklungsmöglichkeiten bei Patenten sehen die Experten von Bulle & Bär Research in Neuralstem nach der Kurskonsolidierung ein interessantes langfristiges Investment. Durch den hohen Freefloat von über 95% ist nach der Kurskonsolidierung auch kurzfristiges Kurspotential vorhanden.

Über Neuralstem Inc.: Neuralstem's patentierte Technologien ermöglichen es erstmalig neuronale Stammzellen des menschlichen Gehirns und der Wirbelsäule in kommerziellen Mengen zu produzieren, sowie deren Zellreifung in reife physiologisch relevante Neuronen und Gliazellen zu gewährleisten. Neuralstem ist auf viele neurologische Hauptkrankheiten des zentralen Nervensystems spezialisiert. Kürzlich begann die erste klinische Phase zur Anwendung dieser Technologien bei der Behandlung von ALS (Lou Gehrig Krankheit). Neuralstem hat ein neuartiges Antidepressivum entwickelt, welches sich ebenfalls in der ersten klinischen Phase befindet und ein reiches Arsenal an Patenten für zukünftige Produktentwicklungen.

Neuralstem Inc. 9700 Great Seneca Highway Rockville, MD 20850 United States

[e-mail] www.neuralstem.com

[Jockelsoy]

[iDes weiteren hat Neuralstem ein neuartiges Antidepressivum namens NSI-189 entwickelt, welches die Behandlung von Depressionen und anderen Krankheiten mit Gedächtnisschwund schlagartig revolutionieren könnte.][/i]


Na klasse ... da kann man sich bei fallenden Kursen seine Dividende ja als Pillen ausschütten lassen



grüsse

[kfz]

War etwas zu früh, aber wir kommen nun in die Gänge!!!

[kfz]

Ist gut für Firma und Aktienpreis !!

Press Release Source: Neuralstem, Inc. On Friday January 28, 2011, 7:00 am
ROCKVILLE, Md., Jan. 28, 2011 /PRNewswire/ -- Neuralstem, Inc. (Amex:CUR - News) announced that it has reach a settlement with ReNeuron, Ltd. ending litigation between the parties. The confidential settlement agreement resolves all claims asserted by Neuralstem against ReNeuron in Neuralstem, Inc. v. ReNeuron, Ltd., Case No. CV 08-02168 R (AGRx), which was pending in the United States District Court for the Central District of California. Although the contents of the agreement have not been disclosed, ReNeuron has agreed to immediately compensate Neuralstem, as well as to make future milestone and royalty payments to Neuralstem based on ReNeuron's development of certain products at issue in the case.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"We are pleased to have settled this dispute and that the parties have put this matter behind them," said Richard Garr, Chief Executive Officer of Neuralstem.

[RedBullish]

Neuralstem geht bald durch die Decke! Bin gespannt auf die nächste Pressemitteilung... ich hab mich knapp über 2 USD eingedeckt! Vor 3.50 USD gehe ich nicht raus.

[kfz]

Wie ich höre geht die Firma die nächsten Wochen auf Roadschow !!!!
RedBullish du hast die richtige Ahnung ich sehe Kurse 6-15 US$ noch dieses Jahr!!! und das ist nicht hochgeriffen! Die News kommen jetzt Monat für Monat!!!

[kfz]

Alle Käufe unter 2,00 Dollar sind ein Schnäppchen !!!!

[kfz]

Es geht in die richtige Richtung an der Amex -es wird gecleant !!! Nächste Woche über 2,00 $ und dann up up in the sky!!

[kfz]

Our rating system posted a BUY today, upgraded from lower rating. The market seems to be ready for a new bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, a new upward move is expected.

[kfz]

4 FDA approvals this Q (Mcap 96 Mil) 3 BAGGER 7-Feb-11 05:37 am RALLYYYYYYY HAS JUST BEGUN ........ENJOY THE RIDE TO 20$++


With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Get in now before the stock gets discovered.GLTA


Anika Therapeutics (ANIK)

Market-Cap: 126 Mil
Cash: 26 Mil
Price: 9.30

Shares Out: 13.5



UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.

4 FDA approvals this Q (Mcap 96 Mil) 3 BAGGER 7-Feb-11 05:37 am RALLYYYYYYY HAS JUST BEGUN ........ENJOY THE RIDE TO 20$++


With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Get in now before the stock gets discovered.GLTA


Anika Therapeutics (ANIK)

Market-Cap: 126 Mil
Cash: 26 Mil
Price: 9.30

Shares Out: 13.5



UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.


4 FDA approvals this Q (Mcap 96 Mil) 3 BAGGER 7-Feb-11 05:37 am RALLYYYYYYY HAS JUST BEGUN ........ENJOY THE RIDE TO 20$++


With a market value of $96 million, Anika Therapeutics (ANIK) is a hidden growth story in the biotech arena .ANIK has been profitable for each of the past seven years.

2011 Price Target: $25.00+ .Buy with both hands now and you will make a lot of money with the upcoming FDA approvals .Get in now before the stock gets discovered.GLTA


Anika Therapeutics (ANIK)

Market-Cap: 126 Mil
Cash: 26 Mil
Price: 9.30

Shares Out: 13.5



UPCOMING MILESTONES :

Monovisc (osteoarthritis) (PMA) FDA approval in 1Q 2011 << Blockbuster Potential

Hyaloglide 510(K) expected FDA approval 1Q 2011

Hyalonect 510(K) expected FDA approval 1Q 2011

Hyalofast 510(K) expected FDA approval 1Q 2011



FAB has commercialized three joint health products that Anika is planning to market in the United States along with MONOVISC™, upon its approval by the FDA. These FAB products include:

* Hyaloglide®, a gel used following tendon and/or peripheral nerve surgery;

* Hyalonect®, a knitted mesh used as a bone graft wrap; and

* Hyalofast™, a non woven matrix of HA used in arthroscopic surgery for the repair of chondral and osteochondral lesions.

We believe these products will only require FDA 510K clearance. These three products – as well as most others in FAB’s portfolio – come with a meaningful clinical data package.

Our goal is to obtain FDA clearance for Hyaloglide, Hyalonect and Hyalofast by the end of Q1 2011. We are building a direct sales force to market MONOVISC in the United States, and adding these three products to our portfolio should provide us with the critical mass we need to more effectively penetrate the domestic orthopedic/joint health market.

[kfz]

run run run !!!!!! 2,35 $ wow

[kfz]

ROCKVILLE, Md., Feb. 9, 2011 /PRNewswire/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted it orphan drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS) with its human spinal cord derived neural stem cells (NSI-566RSC#, currently in a Phase I safety study to evaluate the safety of the product and the surgical route of administration in a wide range of ALS patients.

#Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

"Congress passed the Orphan Drug Act because it recognized that adequate drugs for many rare diseases have not been developed," said Richard Garr, president and CEO of Neuralstem. "The designation of our spinal cord stem cells as an orphan drug underscores the importance of developing effective treatments for patients with ALS. In addition to providing a seven-year term of market exclusivity for our stem cells for ALS upon FDA approval, Orphan Drug Designation also positions Neuralstem to take advantage of certain financial and regulatory benefits, including government grants for conducting clinical trials, waiver of FDA user fees for the submission of a Biologics License Application for NSI-566RSC, and certain tax credits. It is an important step forward for the company."

[kfz]

[kfz]

Neuralstem (AMEX:CUR), ALS Clinical Trial includes Endpoints
February 10th, 2011 Henry McCusker Leave a comment Go to comments
CUR updated the progress of its ongoing Phase I clinical trial of the spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig’s disease) at Emory University in Atlanta, Georgia.

The Phase I trial to evaluate the safety of CUR’s spinal cord stem cells in the treatment of ALS, the 1st FDA approved ALS stem cell trial has been underway since 1/10.

The trial plans to enroll up to 18 ALS patients;
All of the first 6 patients treated in the trial were non-ambulatory. Of these, the first 3 received 5 injections each, unilaterally, in the lumbar region of the spinal cord. The next 3 patients received 10 injections each, bilaterally in the lumbar region. All remaining trial patients are ambulatory, and therefore represent earlier stages of disease progression. Of the ambulatory group, the first 3 patients received 5 injections each, unilaterally, in the lumbar region. The next 3, which have just been approved, will receive 10 injections each, bilaterally, in the lumbar region;
After the required FDA approval, the final 6 patients in the trial will receive injections in the cervical region.
The Bottom Line: While the trial is evaluating only the safety of the cells and procedure, it includes exploratory endpoints: attenuation of motor function loss, maintenance of respiratory capacity, and stabilization of patients along the ALS functional rating scale. The trial’s Safety Monitoring Board unanimously approved moving to the last group of ALS patients in the safety trial. CUR closed up $0.31 (16.06%) to $2.24 on 2/9/11 upon Orphan Drug Designation.

[kfz]

Wie ich höre geht die Kiste auf Roadshow nächst Woche in den USA

[RedBullish]

kommen kaum verkäufe rein. ich glaube bald gehts los in richtung 5 usd!